Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW)

The terms people hike is successful effect to a important summation successful the fig of Transcatheter Aortic Valve Replacement (TAVR) procedures. After surveying physicians who execute the procedure, the results bespeak important maturation successful TAVR. Likewise, the results constituent to betterment successful TAVR marketplace fundamentals. The results align with the company’s gross increasing by 10% successful the 3rd quarter, driven by maturation successful the TAVR division, which accounts for 75% of full revenue. It is the strongest maturation for the part successful caller years.

Earlier, connected January 9, TD Cowen upgraded Edwards Lifesciences to a Buy from Hold and raised the terms people to $97 from $90. The terms people hike is successful effect to the institution entering what the probe steadfast touts arsenic a renewed maturation cycle, driven by expanded indications for transcatheter aortic valve replacement (TAVR).

Edwards Lifesciences Corporation (NYSE:EW) is simply a aesculapian exertion institution that develops and provides patient-focused innovations for bosom conditions, specializing successful structural bosom illness (artificial bosom valves, repair devices for mitral/tricuspid valves) and captious attraction monitoring.

While we admit the imaginable of EW arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.